Navitor Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference

CAMBRIDGE, Mass., November 20, 2018 – Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing innovative therapeutics targeting the activity of mTORC1, or Complex 1 of the mechanistic target of rapamycin, for neurological disorders and chronic diseases of aging, today announced that Thomas E. Hughes, Ph.D., Chief Executive Officer, will present a corporate overview at the 30th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 27, 2018 at 1:10 p.m. Eastern time.

About Navitor
Navitor Pharmaceuticals, Inc. is realizing the potential of modulating mTORC1, a master regulator of cellular metabolism, to develop a pipeline of therapeutics that help patients live longer and healthier lives. Our industry-leading team is unlocking the promise of recent discoveries in mTORC1 biology to address a broad range of chronic diseases. Our initial clinical application is a first-in-class drug to address unmet needs in severe depression. For more information, please visit

Argot Partners
Laura Perry
Stephanie Marks